Research programme: CAR-CIK therapeutics - CoImmune/Memorial Sloan Kettering Cancer Center
Latest Information Update: 07 Feb 2023
At a glance
- Originator CoImmune
- Developer CoImmune; Memorial Sloan-Kettering Cancer Center
- Class Antineoplastics; Cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Cytokine-induced killer cell replacements; Immunologic cytotoxicity
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Lymphoma
Most Recent Events
- 02 Feb 2023 Preclinical trials in Lymphoma in USA (Parenteral) as of February 2023
- 02 Feb 2023 Adverse events and pharmacodynamics data from preclinical studies in Lymphoma released by CoImmune
- 18 Oct 2021 CoImmune enters a licensing agreement with Memorial Sloan Kettering Cancer Center for the development of CAR-CIK Therapies to treat Solid tumours